RxAnte’s RxEffectTM Solution Improves Patient Medication Adherence by Enabling Clinicians to Deliver Better Care for Their Highest-Risk Patients
McLean, VA (PRWEB) May 01, 2014 -- Today, RxAnte Inc., a health care predictive analytics and technology company that specializes in improving the use of prescription medications, announced positive results from its 2013 pilot program to for improving medication adherence in collaboration with Medicare Advantage plans and healthcare providers.
RxEffect™, the company’s provider-facing product that is enabled by advanced analytics, uses health care claims data to provide timely and actionable information and outcomes-based incentives to health care professionals who are accountable for improving medication use.
The pilot included 24,000 Medicare Advantage members at risk of becoming non-adherent to blood pressure, cholesterol, and diabetes medications. The patients were attributed to approximately 4,800 prescribers belonging to 570 physician practices in 11 states. Results of the 2013 RxEffect pilot included, positive uptake by physician practices and significant improvement in adherence rates sufficient to improve the plans’ Medicare Star Ratings. Detailed results are being submitted to a medical journal for publication.
Using predictive modeling technology, RxEffect carefully selected the patients who most need additional engagement by health care professionals and awarded financial bonuses to physician practices each quarter when patients’ adherence to blood pressure, diabetes, and cholesterol medications achieved targeted improvements. According to Dr. Josh Benner, Founder and CEO of RxAnte, “Scientists who study medication adherence have known for years that health care providers are best equipped to address their patients’ concerns, knowledge, commitment, and health care preferences regarding prescription medications. Yet in most practices prescribers have limited information about their patients’ use, and significant economic and workflow barriers prevent them from doing all they can to improve adherence.”
RxAnte’s senior vice president for strategy and business development, Aaron McKethan, explained how the RxEffect program overcomes these challenges: “By helping clinical staff to identify the patients who most need extra support about their prescription medications, and by providing information from best-available evidence about how to provide support to each patient, we’ve enabled providers to engage their patients more meaningfully and directly. We know that simply telling doctors to work harder is not sufficient; we have to give doctors and their teams useful and timely information and meaningful incentives so they in turn can provide extra support to the patients who need it most.”
On April 1, RxAnte launched the 2014 version of RxEffect, including several enhancements suggested by practices and their patients. In addition, the program includes added features to help health plan sponsors manage their relationship with participating practices. “By making RxEffect an easy-to-use tool that helps clinicians know who needs extra support and how to give it, we expect to see even more dramatic improvements in patient outcomes this year,” Benner said.
About RxAnte
RxAnte health care predictive analytics and decision support improves population-level medication use on behalf of health plans, pharmacy benefit management companies, pharmacy chains, and health care providers. The health technology company is transforming how organizations work with health care professionals, care management intervention providers, and patients to promote the safe and effective use of prescription medications. Created by subject matter experts in medication adherence, health IT, and advanced analytics, the “RxAnte System” is a patent-pending platform that includes predictive and decision analytics, advanced evaluation methods, and an innovative platform for provider engagement. Learn more at http://www.rxante.com or follow us on Twitter.
Matt Gagalis, RxAnte, http://www.rxante.com, +1 617-529-2487, [email protected]
Share this article